Health Services Research| Volume 155, P55-61, September 2021

Patient Preferences and Treatment Decisions for Prostate Cancer: Results From A Statewide Urological Quality Improvement Collaborative



      To examine the relationship between influential factors and treatment decisions among men with newly diagnosed prostate cancer (PCa).


      We identified men in the Michigan Urological Surgery Improvement Collaborative registry diagnosed with localized PCa between 2018-2020 who completed Personal Patient Profile-Prostate. We analyzed the proportion of active surveillance (AS) between men who stated future bladder, bowel, and sexual problems (termed influential factors) had “a lot of influence” on their treatment decisions versus other responses. We also assessed the relationship between influential factors, confirmatory testing results and choice of AS.


      A total of 509 men completed Personal Patient Profile-Prostate. Treatment decisions aligned with influential factors for 88% of men with favorable risk and 49% with unfavorable risk PCa. A higher proportion of men who identified bladder, bowel and sexual concerns as having “a lot of influence” on their treatment decision chose AS, compared with men with other influential factors, although not statistically significant (44% vs 35%, P = .11). Similar results were also found when men were stratified based on PCa risk groups (favorable risk: 78% vs 67%; unfavorable risk: 17% vs 9%, respectively). Despite a small sample size, a higher proportion of men with non-reassuring confirmatory testing selected AS if influential factors had “a lot of influence” compared to “no influence” on their treatment decisions.


      Men's concerns for future bladder, bowel, and sexual function problems, as elicited by a decision aid, may help explain treatment selection that differs from traditional clinical recommendation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Cancer Institute. Cancer Stat Facts: Prostate Cancer. Accessed January 23, 2020. Available at:

        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • Cooperberg MR
        • Broering JM
        • Carroll PR.
        Time trends and local variation in primary treatment of localized prostate cancer.
        J Clin Oncol. 2010; 28: 1117-1123
        • Mahal BA
        • Butler S
        • Franco I
        • et al.
        use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the united states, 2010-2015.
        JAMA. 2019; 321: 704
        • Cooperberg MR
        • Carroll PR
        Trends in management for patients with localized prostate cancer, 1990-2013.
        JAMA. 2015; 314: 80
        • Légaré F
        • Adekpedjou R
        • Stacey D
        • et al.
        Interventions for increasing the use of shared decision making by healthcare professionals. Cochrane effective practice and organisation of care group, ed.
        Cochrane Database Syst Rev. 2018; (Published online)
        • Berry DL
        • Hong F
        • Blonquist TM
        • et al.
        Decision support with the personal patient profile-prostate: a multicenter randomized trial.
        J Urol. 2018; 199: 89-97
        • Feldman-Stewart D
        • Tong C
        • Siemens R
        • et al.
        The impact of explicit values clarification exercises in a patient decision aid emerges after the decision is actually made: evidence from a randomized controlled trial.
        Med Decis Mak Int J Soc Med Decis Mak. 2012; 32: 616-626
        • Bosco JL
        • Halpenny B
        • Berry DL.
        Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer.
        Health Qual Life Outcomes. 2012; 10: 123
        • Lucas SM
        • Kim T-K
        • Ghani KR
        • et al.
        Establishment of a web-based system for collection of patient-reported outcomes after radical prostatectomy in a statewide quality improvement collaborative.
        Urology. 2017; 107: 96-102
        • Ginsburg KB
        • Montie JE
        • Cher ML.
        Defining quality metrics for active surveillance: the music experience.
        J Urol. 2020; (Published online)
        • Berry DL
        • Halpenny B
        • Wolpin S
        • et al.
        Development and evaluation of the personal patient profile-prostate (P3P), a web-based decision support system for men newly diagnosed with localized prostate cancer.
        J Med Internet Res. 2010; 12: e67
        • Kaye DR
        • Qi J
        • Morgan TM
        • et al.
        Association between early confirmatory testing and the adoption of active surveillance for men with favorable-risk prostate cancer.
        Urology. 2018; 118: 127-133
        • Ginsburg KB
        • Jacobs JC
        • Qi J
        • et al.
        Impact of early confirmatory tests on upgrading and conversion to treatment in prostate cancer patients on active surveillance.
        Urology. 2021; 147: 213-222
        • Kaye DR
        • Qi J
        • Morgan TM
        • et al.
        Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
        BJU Int. 2019; 123: 846-853
      2. Paudel R, Ferrante S, Maitland C, et al. Implementation of prostate cancer treatment decision aid in michigan: a qualitative study. Implement Sci Commun Submiss.

        • Sanda MG
        • Cadeddu JA
        • Kirkby E
        • et al.
        Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. part i: risk stratification, shared decision making, and care options.
        J Urol. 2018; 199: 683-690
        • Feldman-Stewart D
        • Tong C
        • Brundage M
        • Bender J
        • Robinson J.
        Making their decisions for prostate cancer treatment: Patients’ experiences and preferences related to process.
        Can Urol Assoc J. 2018; 12: 616-626
        • Brooks JV
        • Ellis SD
        • Morrow E
        • Kimminau KS
        • Thrasher JB.
        Patient factors that influence how physicians discuss active surveillance with low-risk prostate cancer patients: a qualitative study.
        Am J Mens Health. 2018; 12: 1719-1727
        • Zeliadt SB
        • Ramsey SD
        • Penson DF
        • et al.
        Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.
        Cancer. 2006; 106: 1865-1874
        • Thera R
        • Carr DrT
        • Groot DrG
        • Baba N
        • Jana DrK
        Understanding medical decision-making in prostate cancer care.
        Am J Mens Health. 2018; 12: 1635-1647
        • Lane GI
        • Ellimoottil C
        • Wallner L
        • Meeks W
        • Mbassa R
        • Clemens JQ.
        Shared decision-making in urologic practice: results from the 2019 AUA census.
        Urology. 2020; (Published onlineS009042952030950X)